Ask about this productRelated genes to: CD276 antibody
- Gene:
- CD276 NIH gene
- Name:
- CD276 molecule
- Previous symbol:
- -
- Synonyms:
- B7-H3, B7H3, B7RP-2
- Chromosome:
- 15q24.1
- Locus Type:
- gene with protein product
- Date approved:
- 2005-03-04
- Date modifiied:
- 2016-10-05
Related products to: CD276 antibody
Related articles to: CD276 antibody
- Although metabolic dysregulation serves as a pivotal hallmark in glioma, the detailed information about the lipid metabolism regulation is largely unknown. In the context of this investigation, we have identified B7-H3 - an immune checkpoint molecule of the B7 family - as a regulator of lipid metabolism in glioma. - Source: PubMed
Publication date: 2026/05/07
Hu XiaohanZhang LiuqingLi YuepengWang JianweiQi WanqingAn JingnanLi XiaoweiYang YuanWeng ZhenLi FangXu Yunyun - Metastatic or locally advanced penile cancer (PeCa) has limited systemic treatment options and a 5-year survival rate of ~10% in metastatic disease. Using the in vitro and ex vivo models we preclinically assessed CC-3, a B7-H3xCD3 bispecific antibody (bsAb) currently in a Phase I basket trial (NCT05999396). - Source: PubMed
Publication date: 2026/05/01
Kielbik AleksanderBahlinger VeronikaSchürch Christian MBarcena Maria LuisaVakhrusheva OlesyaThomas AnitaTsaur IgorHeitmann Jonas SSalih Helmut RHagelstein Ilona - Prostate cancer remains a leading cause of cancer-related mortality in men. Although PSMA-directed theranostics have achieved clinical success, heterogeneous expression and therapy-induced downregulation limit their broad applicability. B7-H3 (CD276), which is highly and stably expressed in prostate cancer, represents a promising alternative theranostic target. - Source: PubMed
Publication date: 2026/04/16
Qiu YongkangGu TingfeiWang TianyaoMulati YelinSun XinyaoYang QiSong LeleYuan TingtingFan YuKang LeiCai Weibo - : B7-H3, a type I transmembrane glycoprotein belonging to the B7 superfamily, is an attractive target for antitumor therapies. B7-H3 demonstrates aberrant overexpression in various types of solid tumors while showing limited and low expression in normal human organs. Various types of treatment targeting B7-H3 have been reported. Among these treatments, antibody-drug conjugates (ADCs) have shown potent activity, and several clinical trials, including DS7300a and MGC018, are currently ongoing. : Here, we constructed CD276-8 ADC, composed of the anti-B7-H3 antibody CD276-8 with moderate affinity, an enzymatically cleavable tetra-peptide-based linker and DXd. Characteristics, including in vitro binding affinity and internalization activity, were assessed by bio-layer interferometry (BLI), flow cytometry and high content analysis (HCA). The cytotoxicity of CD276-8 ADC was evaluated in cell lines expressing B7-H3. Pharmacokinetic profiles and antitumor activity were evaluated in mouse models in vivo. Finally, the developability of CD276-8 ADC was assessed with plasma stability, accelerated stability and freeze-thaw studies using LC-MS and HPLC. : Characterization in vitro demonstrated the moderate affinity and acceptable internalization activity of CD276-8 ADC. In addition, CD276-8 ADC exhibited potent antitumor activities in B7-H3-positive cell line-derived xenograft (CDX) models with acceptable pharmacokinetic profiles, although it showed less potent cytotoxicity in various cell lines in vitro, indicating acceptable developability. : We developed CD276-8 ADC, a B7-H3-targeting ADC with moderate affinity, which delivers the TOP1 inhibitor DXd. This design combined moderate affinity and acceptable pharmacokinetics, resulting in potent antitumor efficacy in vivo. Our study suggests that affinity optimization could be a useful consideration for enhancing ADC efficacy, positioning CD276-8 ADC as a promising therapeutic for B7-H3-expressing solid tumors. - Source: PubMed
Publication date: 2026/04/08
Zhang ZiyuZong HuifangLi ZhenWang ShushengXiao XiaodongXie YueqingZhu Jianwei - Mycosis fungoides (MF) is the predominant subtype of cutaneous T-cell lymphoma, whereas large plaque parapsoriasis (LPP) closely resembles early-stage MF, making differential diagnosis challenging. Immune markers, such as CD47, CD163, and B7-H3, play crucial roles in tumor immune evasion and macrophage polarization. However, their expression profiles and potential diagnostic or prognostic implications in early-stage MF and LPP remain poorly defined. Therefore, this study aimed to evaluate the expression of CD47, CD163, and B7-H3 in early-stage MF and LPP and analyze their associations with clinicopathological characteristics and patient outcomes. This retrospective study evaluated the immunohistochemical expression of CD47, CD163, and B7-H3 in 46 patients with early-stage mycosis fungoides (MF) and 46 patients with large plaque parapsoriasis (LPP). Expression levels were assessed using an immunoreactivity scoring system and analyzed for their associations with clinical parameters and disease-free survival (DFS). The study included patients diagnosed and followed at Sivas Cumhuriyet University between 1 March 2015 and 31 March 2025. : High CD47 expression was detected in 72.7% of MF patients, high B7-H3 expression in 45.7%, and high CD163 expression in 46.7% compared with LPP patients ( < 0.001). These markers showed positive correlations, and elevated expression, especially of B7-H3 and CD163, was associated with shorter disease-free survival in univariate analysis. : The higher expression of CD47, CD163, and B7-H3 in early-stage MF compared with LPP suggests that these markers may contribute to the differential diagnosis and could represent potential therapeutic targets; however, their independent prognostic value requires confirmation in larger studies. - Source: PubMed
Publication date: 2026/04/02
Yasak Guner RukiyeYüceer Ramazan OguzUnsal Ahmet Turan